当前位置:首页 - 行情中心 - 科源制药(301281) - 财务分析 - 现金流量表

科源制药

(301281)

  

流通市值:33.74亿  总市值:51.50亿
流通股本:7095.20万   总股本:1.08亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金175,247,001.4473,885,748.85299,180,405.94202,183,174.02
  收到的税费返还--502,727.86566,215.25
  收到其他与经营活动有关的现金9,966,015.6444,649,924.8239,899,125.3516,120,255.6
  经营活动现金流入小计185,213,017.08118,535,673.67339,582,259.15218,869,644.87
  购买商品、接受劳务支付的现金70,190,818.6431,978,248.4496,777,908.1648,600,286.13
  支付给职工以及为职工支付的现金55,600,999.0926,878,547.69109,436,259.1183,313,526.13
  支付的各项税费18,539,698.213,476,826.5914,707,958.814,860,780.22
  支付其他与经营活动有关的现金-1,375,670.9325,080,071.7975,191,055.3944,855,131.06
  经营活动现金流出小计142,955,845.0187,413,694.51296,113,181.46191,629,723.54
  经营活动产生的现金流量净额42,257,172.0731,121,979.1643,469,077.6927,239,921.33
二、投资活动产生的现金流量:
  收回投资收到的现金270,000,000-596,708,619.72490,040,412.48
  取得投资收益收到的现金1,431,684.041,200,183.934,617,837.072,012,729.8
  处置固定资产、无形资产和其他长期资产收回的现金净额3,260.39-500,578.99198,968
  收到的其他与投资活动有关的现金-7,100,000-21,085,848.52
  投资活动现金流入小计271,434,944.438,300,183.93601,827,035.78513,337,958.8
  购建固定资产、无形资产和其他长期资产支付的现金64,876,490.1227,630,358.68137,050,696.11108,642,394.92
  投资支付的现金448,885,902.259,000,000343,322,620.87534,330,041.67
  支付其他与投资活动有关的现金--38,011.25-
  投资活动现金流出小计513,762,392.3736,630,358.68480,411,328.23642,972,436.59
  投资活动产生的现金流量净额-242,327,447.94-28,330,174.75121,415,707.55-129,634,477.79
三、筹资活动产生的现金流量:
  取得借款收到的现金93,879,517.6644,398,432.4570,161,627.8955,395,301.38
  筹资活动现金流入小计93,879,517.6644,398,432.4570,161,627.8955,395,301.38
  偿还债务支付的现金12,124,719.540,0003,558,384.983,478,384.98
  分配股利、利润或偿付利息支付的现金8,143,231.991,158,514.6224,820,297.3823,948,271.37
  筹资活动现金流出小计20,267,951.491,198,514.6228,378,682.3627,426,656.35
  筹资活动产生的现金流量净额73,611,566.1743,199,917.8341,782,945.5327,968,645.03
四、汇率变动对现金及现金等价物的影响-748,311.04-204,929.59453,917.96488,714.31
五、现金及现金等价物净增加额-127,207,020.7445,786,792.65207,121,648.73-73,937,197.12
  加:期初现金及现金等价物余额298,891,416.94298,891,416.9491,769,768.2191,769,768.21
  期末现金及现金等价物余额171,684,396.2344,678,209.59298,891,416.9417,832,571.09
补充资料:
  净利润64,470,616.69-16,376,551.12-
  资产减值准备-1,920,584.69-19,476,562.68-
  固定资产和投资性房地产折旧22,687,801.11-45,382,820.03-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧22,687,801.11-45,382,820.03-
  无形资产摊销5,015,836.5-6,588,819.94-
  长期待摊费用摊销-696,123.96-303,526.17-
  处置固定资产、无形资产和其他长期资产的损失---303,640.29-
  固定资产报废损失6,165.68-565,413.44-
  公允价值变动损失-163,972.6---
  财务费用1,206,385.28--437,347.32-
  投资损失-307,322.09--5,925,403.13-
  递延所得税-2,340,691.75--687,897.25-
  其中:递延所得税资产减少-767,984.02--1,204,353.49-
    递延所得税负债增加-1,572,707.73-516,456.24-
  存货的减少26,421,773.49--34,262,804.34-
  经营性应收项目的减少-153,768,696.96--31,870,729.66-
  经营性应付项目的增加69,371,934.4-28,263,206.3-
  其他12,274,050.97---
  现金的期末余额171,684,396.2-298,891,416.94-
  减:现金的期初余额298,891,416.94-91,769,768.21-
  现金及现金等价物的净增加额-127,207,020.74-207,121,648.73-
公告日期2026-08-272026-04-242026-04-162025-10-24
审计意见(境内)标准无保留意见
TOP↑